4-Aminoacetanilide, also known as p-aminoacetanilide, is a white, crystalline organic compound with the formula C8H10N2O. It is a derivative of acetanilide, where an amino group is substituted at the para position. This compound is primarily used as an intermediate in the synthesis of various dyes, pharmaceuticals, and other chemicals. It is synthesized by the acetylation of p-phenylenediamine with acetic anhydride. While its primary use is in industrial applications, it has also been studied for its potential biological activity. However, it is not a commonly used pharmaceutical due to its potential toxicity. The compound has been reported to exhibit antimicrobial and anti-inflammatory properties, and it has also been investigated as a potential anti-cancer agent. Research on 4-aminoacetanilide primarily focuses on its potential applications in materials science, drug development, and chemical synthesis.'
| ID Source | ID |
|---|---|
| PubMed CID | 31230 |
| CHEMBL ID | 1318876 |
| SCHEMBL ID | 92049 |
| MeSH ID | M0509708 |
| Synonym |
|---|
| HMS1760L01 |
| p-acetaminoaniline |
| smr001224520 |
| MLS002152920 |
| BB 0216502 |
| acetamide, n-(4-aminophenyl)- |
| 4-(acetylamino)aniline |
| nsc2135 |
| 4'-aminoacetanilid |
| c.i. 76005 |
| c.i. oxidation base 19 |
| fourrine 88 |
| nsc-2135 |
| 122-80-5 |
| n-acetyl-p-phenylenediamine |
| 4-acetamidoaniline |
| p-acetamidoaniline |
| n-(p-aminophenyl)acetamide |
| acetyl-p-phenylenediamine |
| acetanilide, 4'-amino- |
| fourrine a |
| 4-aminoacetanilide , |
| p-(acetylamino)aniline |
| 4'-aminoacetanilide |
| acetparamin |
| p-acetoaminoaniline |
| 1-amino-4-(acetylamino)benzene |
| p-acetylaminoaniline |
| wln: zr dmv1 |
| n-acetyl-p-fenylendiamin |
| p-aminoacetanilide |
| inchi=1/c8h10n2o/c1-6(11)10-8-4-2-7(9)3-5-8/h2-5h,9h2,1h3,(h,10,11 |
| n-(4-aminophenyl)acetamide |
| p-amino acetanilide |
| NCGC00091382-01 |
| einecs 204-576-6 |
| nsc 2135 |
| 4'-aminoacetanilid [czech] |
| n-acetyl-p-fenylendiamin [czech] |
| brn 0742888 |
| ai3-00069 |
| ccris 2879 |
| STK299393 |
| OPREA1_124717 |
| 4'-aminoacetanilide, 99% |
| A0106 |
| n-acetyl-1,4-phenylenediamine |
| AKOS000108321 |
| A804968 |
| 4-acetamidoaniline; n-(4-aminophenyl)acetamide; n-acetyl-p-phenylenediamine;4-aminoacetanilide |
| NCGC00091382-02 |
| ih5ox0i3z9 , |
| 4-13-00-00137 (beilstein handbook reference) |
| unii-ih5ox0i3z9 |
| HMS3039E03 |
| BBL008068 |
| tox21_200754 |
| dtxcid704455 |
| cas-122-80-5 |
| NCGC00258308-01 |
| dtxsid7024455 , |
| FT-0617543 |
| n1-(4-aminophenyl)acetamide |
| p-aminoacetanilide [mi] |
| aminoacetanilide, p- |
| SCHEMBL92049 |
| 4-amino acetanilide |
| 4-acetylaminoaniline |
| n-(4-aminophenyl)-acetamide |
| n-(4-amino-phenyl)-acetamide |
| 4-acetaminoaniline |
| p-acetamino aniline |
| p-aminoacetanilid |
| 4-acetoamidoaniline |
| n-acetyl-1,4-benzenediamine |
| paracetamin |
| W-109456 |
| CHEMBL1318876 |
| mfcd00007853 |
| F0020-1819 |
| n-(4-aminophenyl)acetamide. |
| Z56926521 |
| 4`-aminoacetanilide |
| 1219802-76-2 |
| 4/'-aminoacetanilide |
| 7E-930 |
| Q27280726 |
| 4'-aminoacetanilide--d4 |
| EN300-17406 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.9607 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 69.5673 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 10.1739 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 55.2593 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 22.1859 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 12.5910 | 0.0100 | 39.5371 | 1,122.0200 | AID588545; AID588547 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 31.0746 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 47.3079 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 2.6603 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleoplasm | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nuclear body | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| chromatin | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.82) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||